.. Adamis receives patents for APC-200 prostate cancers drug in South Africa, Singapore Adamis Pharmaceuticals Company , today announced the technology which constitutes its compound APC-200 was granted patents in Singapore and South Africa recently. These patents significantly fortify the Adamis APC-200 patent portfolio for the usage of APC-200 in the treatment of early and late stage prostate cancers. APC-200 is usually a small molecule formulation that is developed for oral administration.Now, experts from the Perelman College of Medicine at the University of Pennsylvania have discovered that it might have a new use for the 21st century: protecting healthful tissues and organs from the dangerous effects of radiation. In a study just published in BMC Cancers, researchers discovered that a diet plan of flaxseed given to mice not merely protects lung cells before exposure to radiation, but can also significantly reduce damage after exposure occurs. There are just a handful of potential mitigators of radiation effect, and do not require is nearly ready for the clinic, says the main investigator Melpo Christofidou-Solomidou, PhD, analysis associate professor of Medication, Pulmonary, Important and Allergy Treatment Division.